cholesterol drugs

American Heart scientific sessions and ALN-PCSsc, an RNAi Investigational Agent

I'm here at the 2015 American Heart Association Scientific Sessions and will bring you many many key points in the next 2 weeks. This meeting is filled with science and results and fascinating new medicines, SPRINT to new blood pressure goals, measurements such as TIMI and DAPT risk scores and so much more.

Experimental medicine for lowering cholesterol shows great promise (ETC-1002)

cannon A new potential weapon fighting cholesterol-ETC-1002 (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is an experimental medicine you should know.

Members Only: 

cannon A new potential weapon fighting cholesterol-ETC-1002 (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is an experimental medicine you should know.

What a complicated name, but not so unusual for medicines still being researched. If you go to www.clinicaltrals.gov, you can search NCT01941836 and see the research involving this fascinating potential medicine. The last publication on this novel cholesterol treatment was by Gutierrez, Rosenberg, MacDougall, et al. The title of the article was Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol-Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes mellitus.

This is especially interesting because people with diabetes have a 2 to 4 fold increased risk of cardiovascular disease. The study conclusions show that LDL and other fats were lowered, CRP (C-reactive protein) improved and blood sugar control (an issue with statins like Lipitor and Crestor) was NOT worsened. In English: Good changes in bad cholesterol without causing sugar problems.

Could it get better? As with many experimental medicines, phase 3 studies (the last phase before sending in the information/data to the FDA) are needed. For now, this looks like the medicine I want to take. It appears that I might lower the dose of my statin (avoiding possible statin side effects), add on ETC-1002 and get the benefit of even lower cholesterol and heart attack risk while keeping my ability to control blood sugar. As always, more to come and we will have the data here when it becomes available.

Zocor (simvastatin) and high dose muscle risks: Safety recommendations by FDA

cannon in New Orleans  The FDA released an 80 mg simvastatin (Zocor, Vytorin, Simcor) news release today, citing safety label changes for the highest dose of this widely used cholesterol-lowering medicine.

Members Only: 

cannon in New Orleans  The FDA released an 80 mg simvastatin (Zocor, Vytorin) news release today, citing safety label changes for the highest dose of this widely used cholesterol-lowering medicine. Roughly 2.1 million prescriptions have been written for products containing this 80 mg dose and the changes made today are the result of FDA review of a 7 year study.

The highest approved dose of simvastatin has been associated with an increased risk of muscle injury (or myopathy)...especially during the first year of use. What the FDA is recommending is that the 80 mg dose should be used only in patients who have been taking this dose for 12 months or more and HAVE NOT had any muscle toxicity. They further added that this dose should NOT be prescribed to new patients. The FDA also revised the labels of combination products that contain simvastatin to caution against combinations with certain other medicines which may increase the blood levels of simvastatin (an undesirable drug-drug interaction).The FDA made its conclusions based on the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine.

It is important to note that such a pattern of increased risk HAS NOT been found with the 40 mg or lower doses. Patients with concerns should talk to their doctors BEFORE making any changes to their medicines.  There is NO DOUBT that lowering of bad (LDLc) cholesterolis a key to decreasing risk of heart attack and stroke. The full FDA news release can be found at www.fda.gov.

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.